Table 1 Baseline clinicopathological characteristics of the 152 epithelial ovarian cancer (EOC) patients involved grouped by training set and validation set.

From: Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition

Variables Total (n = 152) Training group (n = 114) Validated group (n = 38) p-value
Age (years) 58.06 ± 9.47 57.81 ± 10.25 58.10 ± 9.73 0.879
BMI (kg/m2) 22.86 ± 0.73 22.91 ± 0.47 22.85 ± 0.93 0.604
Menopausal status, n (%) 0.924
 Pre/peri-menopause 65 (42.76%) 49 (32.24%) 16 (10.53%)
 Post-menopause 87 (57.24%) 65 (42.76%) 22 (14.47%)
Fertility history, n (%) 0.852
 0–1 82 (53.95%) 62 (40.79%) 20 (13.16%)
 ≥ 2 70 (46.05%) 52 (34.21%) 18 (11.84%)
Tumor size (cm) 7.26 ± 3.15 6.39 ± 4.62 7.37 ± 3.21 0.285
Pathological grade, n (%) 0.765
 G1–2 51 (33.55%) 39 (25.66%) 12 (7.89%)
 G3 101 (66.45%) 75 (49.34%) 26 (17.11%)
FIGO stage, n (%) 0.748
 I–II 39 (25.66%) 30 (19.74%) 9 (5.92%)
 III–IV 113 (74.34%) 84 (55.26%) 29 (19.08%)
Lymph node metastasis, n (%) 72 (47.37%) 52 (34.21%) 20 (13.16%) 0.453
Ascites, n (%) 58 (38.16%) 43 (28.29%) 15 (9.87%) 0.847
Histological type, n (%) 0.954
 Serous 92 (60.53%) 69 (45.39%) 23 (15.13%)
 Mucinous 24 (15.79%) 18 (11.84%) 6 (3.95%)
 Endometrioid 17 (11.18%) 12 (7.89%) 5 (3.29%)
 Others 19 (12.50%) 15 (9.87%) 4 (2.63%)
  1. BMI Body Mass Index, FIGO the International Federation of Gynecology and Obstetrics.